Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Personalized ventilation for ARDS: early trial halted, results uncertain

NCT ID NCT04012073

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether setting a ventilator based on each patient's lung volume could improve outcomes for people with moderate-to-severe acute respiratory distress syndrome (ARDS). The approach used a bedside measurement to tailor the pressure applied during breathing. However, the trial was stopped early after enrolling only 18 participants, so it is not possible to draw firm conclusions about its effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Invasive mechanical ventilation with individualized positive end-expiratory pressure (PEEP) guided by end-expiratory lung volume (EELV) measurement
What this could lead to
If successful, this approach could help doctors set ventilators more precisely for each ARDS patient, potentially reducing lung injury and improving survival.
What could go wrong
The trial was terminated early with only 18 participants, so results are very limited. It is unclear if the method works better than standard care, and any benefits remain unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

18 people

The number who actually took part.

Started

Nov 2022

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility inclusion criteria, according to the ARDS Berlin definition, will be assessed within the first 24 hours from the initiation of invasive mechanical ventilation: 1. Acute respiratory failure within 1 week of a known clinical insult or new or worsening respiratory symptoms; 2. Bilateral infiltrates at the chest x-ray or CT scan, not fully explained by effusions, lobar/lung collapse, or nodules; 3. Respiratory failure not fully explained by cardiac failure or fluid overload; objective assessment required to exclude hydrostatic edema if no risk factor present. 4. PaO2/FiO2 ratio≤150 mmHg after 30 mins - 1 hour of mechanical ventilation with PEEP=5 cmH2O. 5. Written informed consent. Exclusion Criteria: 1. Pregnancy; 2. Pneumothorax; 3. Acute brain injury; 4. Clinical signs of history of decompensated heart failure (New York Heart Association class 3-4 before the acute phase of the disease or documented ejection fraction\<35% or pulmonary capillary wedge pressure\>18 mmHg) or acute coronary syndrome; 5. Intubation as a result of an acute exacerbation of chronic pulmonary disease: chronic obstructive pulmonary disease, asthma, cystic fibrosis, etc; 6. Clinically evident intrinsic PEEP (≥2 cmH2O) during screening visit (End-expiratory pause to achieve Flow=0); 7. BMI\>35; 8. BMI\<15 or body weight\<35 Kg; 9. Any chronic disease requiring long-term oxygen therapy or mechanical ventilation at home; 10. Neuromuscular disease of any kind; 11. Severe chronic liver disease (Child-Pugh C or worse); 12. Bone marrow transplantation or chemotherapy-induced neutropenia; 13. History of liver or lung transplant; 14. Decision to withhold life-sustaining treatment; 15. Need for therapy with inhaled nitric oxide due to documented pulmonary arterial hypertension; 16. Life-threatening hypoxemia deemed to require extracorporeal membrane oxygenation (ECMO); 17. Presence of documented barotrauma; 18. High risk of mortality within 3 months from other than ARDS (severe neurological damage, age \>85 years and cancer patients in terminal stages of the disease). 19. Persistent hemodynamic instability, intractable shock (norepinephrine\>1 mcg/kg/h and/or blood lactate\>5 mmol/L and/or considered too hemodynamically unstable for enrolment in the study by the patient's managing physician). 20. More than 24 hours from endotracheal intubation to the time of the screening visit.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Azienda ospedaliera universitaria di Ferrara-arcispedale Sant'Anna

    Ferrara, Italy

  • Azienda ospedaliero-universitaria Mater Domini

    Catanzaro, Italy

  • Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Fondazione Policlinico Universitaro A. Gemelli IRCCS

    Rome, Italy

  • Ospedale San Gerardo

    Monza, Italy

  • Ospedale San Martino

    Genova, Italy

  • Policlinico Sant'Orsola

    Bologna, Italy

  • Policlinico di Bari

    Bari, Italy

  • SS. Annunziata hospital

    Chieti, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.